₹1,000 crore revenue target by FY28
Management reiterated the long-term goal. Requires quarterly run-rate to reach ₹120-130 crore (currently ₹95 crore) to be in line, supported by capacity expansion and new IBC product line.
Mitsu Chem Plast · forward-looking guidance across the available source record.
Guidance tracker
Management reiterated the long-term goal. Requires quarterly run-rate to reach ₹120-130 crore (currently ₹95 crore) to be in line, supported by capacity expansion and new IBC product line.
Management clarified that the 16.3% Q1 margin reflects operational efficiencies and product mix; normalized sustainable range is 10-12% going forward.
Intermediate Bulk Container manufacturing unit expected to commence commercial operations in Q3, representing a new growth vertical with dedicated machinery.
Management explicitly stated priority on profitability over revenue growth, with quarterly revenue growth expected to be 'similar' to recent quarters (~10-11%).
Management stated 8-10% EBITDA margin is 'reasonable' for the current business mix of commodity and niche products. With operational efficiency and scale, they aspire to 8-15% range at higher turnover.
Long-term goal requires nearly doubling capacity to ~35,000 MT (from ~29,000 MT currently) and approximately doubling gross block. Capex requirements to be announced as plans are finalized.
Management guided that FY27 growth will be 'almost in the same range' as historical ~20% CAGR, with more focus on profitability rather than aggressive top-line expansion.
At 1,000 crore revenue scale, niche products (healthcare furniture components) expected to remain at 15-20% of revenue, expanding in absolute terms alongside commodity products.
Management guided minimum 30% revenue growth for FY27, implying ~₹455 crore revenue, driven by volume expansion to 27,000 tons from current 21,000 tons and new IBC plant commissioning.
The new fully-automatic IBC (Intermediate Bulk Container) plant at Kalapur facility is on track to start operations in Q2 FY27, expected to be a meaningful growth and margin driver given limited competition.
Long-term target of ₹1,000 crore annual revenue by FY28, with healthcare/furniture segment expected to grow to ~20% mix from current 16%, requiring near-tripling of current revenue.
Management stated 10%+ EBITDA margin is sustainable for the business; Q4's 16.45% included 1-2pp one-off benefit. Internal targets are slightly above 10%.